Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Vaccine

• Publication date

  2009-05-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2009.01.083PMID 19200849PMCID PMC5798449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Severe Depletion of Mucosal CD4+ T Cells in AIDS-Free Simian Immunodeficiency Virus-Infected Sooty Mangabeys1

  2007cited by this paper
• Innate Vα14+ natural killer T cells mature dendritic cells, leading to strong adaptive immunity

  2007cited by this paper
• Mucosal adjuvants.

  2005cited by this paper
• Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells

  2005cited by this paper
• Glycolipid antigen induces long-term natural killer T cell anergy in mice.

  2005influential reference
• α-Galactosylceramide Can Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral Infection and Tumor1

  2005cited by this paper
• Mucosal immunity and vaccines

  2005cited by this paper
• A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens.

  2004cited by this paper
• Mucosal immunisation: adjuvants and delivery systems.

  2004cited by this paper
• Severe CD4+ T-Cell Depletion in Gut Lymphoid Tissue during Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in Restoration following Highly Active Antiretroviral Therapy

  2003cited by this paper
• Activation of Natural Killer T Cells by -Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein

  2003cited by this paper
• Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

  2002cited by this paper
• Prolonged IFN-γ–producing NKT response induced with α-galactosylceramide–loaded DCs

  2002cited by this paper
• Mucosal immunity and vaccination against HIV

  2002cited by this paper
• The mucosal immune system: primary target for HIV infection and AIDS.

  2001cited by this paper
• Targeting Human Papillomavirus Type 16 E7 to the Endosomal/Lysosomal Compartment Enhances the Antitumor Immunity of DNA Vaccines against Murine Human Papillomavirus Type 16 E7-Expressing Tumors

  1999cited by this paper
• MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.

  1999cited by this paper
• Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.

  1998cited by this paper
• Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1.

  1995cited by this paper
• Rapid in vivo induction of HIV-specific CD8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120.

  1992cited by this paper
• General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

  1985cited by this paper
• Solid Phase Peptide Synthesis

  1984cited by this paper
• Solid-phase peptide synthesis.

  1977cited by this paper
• Azide solid phase peptide synthesis.

  1970cited by this paper
• Solid phase peptide synthesis. I. the synthesis of a tetrapeptide

  1963cited by this paper

• Synthetic and Biogenic Materials for Oral Delivery of Biologics: From Bench to Bedside.

  2025cites this paper
• Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus.

  2024cites this paper
• NKT Agonist-Antigen Conjugates as Cancer Vaccines.

  2024cites this paper
• Oral administration of DNA alginate nanovaccine induced immune-protection against Helicobacter pylori in Balb/C mice

  2024cites this paper
• A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

  2024cites this paper
• Developing an On‐Resin Synthesis of α‐Galactosylceramide‐Peptide Conjugate Vaccines

  2024cites this paper
• Recent Developments in Oral Delivery of Vaccines Using Nanocarriers

  2023cites this paper
• Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants

  2023cites this paper
• Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines

  2023cites this paper
• 6″-Modifed α-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria

  2022cites this paper
• A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine

  2022cites this paper
• Oral vaccination using microdevices to deliver α-GalCer adjuvanted vaccine afford mucosal immunity.

  2022cites this paper
• iNKT cell agonists as vaccine adjuvants to combat infectious diseases.

  2022cites this paper
• Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice

  2022cites this paper
• Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist

  2021cites this paper
• The role of unconventional T cells in COVID-19

  2021cites this paper
• Role of NKT Cells during Viral Infection and the Development of NKT Cell-Based Nanovaccines

  2021cites this paper
• Polyethylenimine: An Intranasal Adjuvant for Liposomal Peptide-Based Subunit Vaccine against Group A Streptococcus.

  2020cites this paper
• Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization.

  2020cites this paper
• Intranasal Therapeutic Peptide Vaccine Promotes Efficient Induction and Trafficking of Cytotoxic T Cell Response for the Clearance of HPV Vaginal Tumors

  2020cites this paper
• Advances in Oral Subunit Vaccine Design

  2020cites this paper
• Mucoadhesive wafers composed of binary polymer blends for sublingual delivery and preservation of protein vaccines.

  2020cites this paper
• An investigation into the phenotype, function and immunomodulatory properties of in vitro expanded iNKT cells

  2019cites this paper
• Perturbation of mucosal-associated invariant T cells and iNKT cells in HIV infection

  2019cites this paper
• Recent Advances in the Design of Self‐Delivery Amphiphilic Drugs and Vaccines

  2019cites this paper
• An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses

  2019cites this paper
• Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity

  2018cites this paper
• Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection

  2018cites this paper
• The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens

  2018cites this paper
• Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in Mice

  2017cites this paper
• Memory Potential, Molecular Characterization, and Translational Applications of the Novel ThEO/TcEO T Cell Phenotype

  2017cites this paper
• Endogenous and Exogenous Natural Adjuvants for Vaccine Development.

  2017cites this paper
• The Role of Invariant NKT Cells in Immunity

  2016cites this paper
• Intranasal Vaccination Affords Localization and Persistence of Antigen-Specific CD8+ T Lymphocytes in the Female Reproductive Tract

  2016cites this paper
• Assessment of combined vaccination and immune modulation as an anti-tumour therapy

  2016cites this paper
• Selective quantitation of the incorporation of the immunomodulator α-galactosylceramide in liposomes using LC–MS/MS

  2015cites this paper
• Antigen Delivery Systems I: Nonliving Microparticles, Liposomes, and Immune-Stimulating Complexes (ISCOMs)

  2015cites this paper
• Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies

  2015cites this paper
• Regulation of NKT Cell Localization in Homeostasis and Infection

  2015cites this paper
• iNKT Cells and Their Potential Lipid Ligands during Viral Infection

  2015influential citation
• The Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their Products

  2015cites this paper
• Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine

  2015cites this paper
• Sublingual injection of microparticles containing glycolipid ligands for NKT cells and subunit vaccines induces antibody responses in oral cavity.

  2015cites this paper
• Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression.

  2015cites this paper
• CD1d-dependent endogenous and exogenous lipid antigen presentation.

  2015cites this paper
• Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.

  2014cites this paper
• Antigen Delivery Systems as Oral Adjuvants

  2014cites this paper
• Vaccine-induced myeloid cell population dampens protective immunity to SIV.

  2014cites this paper
• Activation of iNKT cells by a distinct constituent of the endogenous glucosylceramide fraction

  2014cites this paper
• Harnessing the antibacterial and immunological properties of mucosal-associated invariant T cells in the development of novel oral vaccines against enteric infections.

  2014cites this paper
• Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant

  2014influential citation
• Invariant NKT Cell Response to Dengue Virus Infection in Human

  2014cites this paper
• Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.

  2014cites this paper
• Sublingual Vaccination Induces Mucosal and Systemic Adaptive Immunity for Protection against Lung Tumor Challenge

  2014cites this paper
• Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy

  2014cites this paper
• Enhancement of recombinant adenovirus vaccine-induced primary but not secondary systemic and mucosal immune responses by all-trans retinoic acid.

  2014cites this paper
• The Influence of Immunization Route on the Adjuvant Effect of alpha-Galactosylceramide

  2013influential citation
• Preclinical and Clinical Development of Synthetic i NKT-Cell Glycolipid Agonists as Vaccine Adjuvants

  2013cites this paper
• Invariant NKT Cells as Novel Targets for Immunotherapy in Solid Tumors

  2012cites this paper
• Mucosal vaccine adjuvants update

  2012cites this paper
• The Role of NKT Cells in the Immune Regulation of Neoplastic Disease

  2012cites this paper
• Natural killer T cell based Immunotherapy.

  2012cites this paper
• Selection of Optimal Adjuvants and Product Factors that Affect Vaccine Immunogenicity

  2011cites this paper
• Selection of Adjuvants for Enhanced Vaccine Potency

  2011cites this paper
• Intranasal but not intravenous delivery of the adjuvant α‐galactosylceramide permits repeated stimulation of natural killer T cells in the lung

  2011influential citation
• Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease.

  2011cites this paper
• of NKT Cells Eosinophilia Is Mediated through the Activation Induced Airway − -Galactosylceramide α

  2011cites this paper
• iNKT cells in microbial immunity: recognition of microbial glycolipids

  2011cites this paper
• Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.

  2011cites this paper
• α-Galactosylceramide–Induced Airway Eosinophilia Is Mediated through the Activation of NKT Cells

  2011cites this paper
• Mucosal HIV vaccines: a holy grail or a dud?

  2010cites this paper
• Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

  2010cites this paper
• A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity.

  2010cites this paper
• CHARACTERIZATION OF ALPHA-GALACTOSYLCERAMIDE AS A MUCOSAL ADJUVANT

  2010cites this paper
• NKT cells in mucosal immunity

  2009cites this paper
• Current World Literature

  2006cites this paper